Novartis named first-ever corporate pharmaceutical partner of the NFL
See how this partnership is turning fan passion into health prevention and enabling better health in our communities.
Discover our medicines
See how our innovative medicines are addressing society's greatest health challenges.
Commitment to patients
From research and development to expanding access, uncover our commitment to improving people's lives.
Inspired by purpose
Learn about our people and culture, and how we're driven by our mission to reimagine medicine.
Novartis 2024 Financial Results
Novartis announces the company’s fourth quarter and 2024 full year financial results.
Committed to Advancing Prostate Cancer
Learn about a bold new partnership helping to reshape the future of cancer care for communities in need.
Latest News
Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis named first-ever corporate pharmaceutical partner of the National Football League
Welcome to where we thrive
Discover how you can join us in our mission to change people's lives.